Skip to main content

Philip Vorwald, Jay LeCoque, Sir Walter Bodmer

Premium
Celsis International this week announced the appointment of Philip Vorwald as vice president and general manager of its Celsis In Vitro Technologies division.
 
Vorwald will be responsible for setting and overseeing the long-term growth strategy of Celsis IVT's ADME-Tox products. Vorwald will report directly to Celsis' CEO, Jay LeCoque.
 
Prior to joining Celsis, Vorwald served as the senior vice president of commercial operations for Cytonome. Prior to joining Cytonome, Vorwald held numerous domestic and overseas management positions with Becton Dickinson's biosciences division. He also worked for Guava Technologies and Delphi in new and emerging business development capacities.
 

 
Oxford Genome Sciences (OGeS) announced this week that it has appointed to its scientific advisory board Sir Walter Bodmer, currently head of the cancer and immunogenetics laboratory in the Weatherall Institute of Molecular Medicine at the University of Oxford.
 
Bodmer is researching the fundamental genetic and biological changes that lead to the development of colorectal cancer. OGeS and Bodmer's team will collaborate on the evaluation of OGeS cancer drug candidates in the area of colorectal cancer.
 
Prior to the Weatherall Institute, Bodmer was the director general of the Imperial Cancer Research Fund. Before joining the Imperial Cancer Research Fund, he was a professor of genetics at the University of Oxford. Bodmer moved to Oxford from Stanford University where he was also a professor of genetics.

The Scan

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.